Effect of Inhaled Colistin on the Treatment of VentilatorAssociated Pneumonia due to Multi-drug Resistant Acinetobacter


1 Trauma and Injury Research Center, Department of Critical Care, Iran University of Medical Sciences, Tehran, Iran.

2 Department of Infectious Disease, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

3 Department of Anesthesiology, School of Medicine, Arak University of Medical Sciences, Arak, Iran.


Background: Ventilator-Associated Pneumonia (VAP) is a hospital pneumonia
that is considered in patients on mechanical ventilation for at least 48 hours
with symptoms of new lower respiratory tract infections being reported in
them. The present study reviews the effect of adding inhaled colistin in the
treatment of ventilator-induced pulmonary infections in Intensive Care Unit
(ICU) patients.
Materials and Methods: In this single blind clinical trial, patients admitted to
the ICU with diagnosis of pulmonary infections caused by ventilator were
investigated. In the treatment group, patients received 150 mg of colistin plus
1,000,000 units inhaled colistin every eight hours and in the control group only
300 mg of colistin every eight hours intravenously was given. Patients were
followed up in terms of clinical findings for seven days after the initial
diagnosis of infection.
Results: The results of this study showed that administration of inhaled colistin
in patients admitted in ICU significantly improved culture indices, leukocyte,
white blood cell count, chest X-ray, chest secretion, CPIS score and
saccharification (SpO2) on the third and seventh days after treatment compared
to the first day.
Conclusion: Considering the positive effect of adding inhaled colistin to the
treatment of patients admitted to ICU with pulmonary infections caused by
ventilator with multi-drug resistant Acinetobacter, the use of combination drug
therapy is recommended.